Technology | Contrast Media | February 02, 2017

Lantheus Medical Imaging Announces FDA Approval of Definity Label Update

Label revision removes cardiac shunt contraindication

Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication

February 2, 2017 — Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The update removes the contraindication statement related to use in patients with a known or suspected cardiac shunt from the U.S. Prescribing Information.

Definity is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal path of the circulatory system, which may present in 10 to 35 percent of patients. These patients were previously excluded from receiving a valuable echo contrast study of the left ventricle. The FDA’s decision to remove the contraindication concerning known or suspected cardiac shunts was based on Lantheus’ submission referencing several publications and data supporting the safety of echocardiography contrast products in patients with cardiac shunts. Information concerning administration in patients with a cardiac shunt appears in the Warnings section of the Definity Prescribing Information.

Neil Weissman, M.D., president of MedStar Health Research Institute (Washington, D.C.), professor of medicine at Georgetown University and past president of the American Society of Echocardiography commented, “The echocardiography medical and scientific community has long demonstrated the safety of echocardiographic contrast agents through published clinical studies which has supported the removal of the contraindication for Definity in patients with cardiac shunts. This is particularly noteworthy as Definity is the most widely used echocardiography agent in the U.S. with published data supporting its safety profile across multiple care settings and across gender and race in adults, including those age 65 and older.”

Weissman continued, “This is an important step toward broader acceptance and appropriate use of echo contrast agents, which can safely and cost effectively provide critical information to help clinicians accurately diagnose and manage patients to achieve better outcomes.”

Up to 20 percent of all resting echocardiography studies and up to 30 percent of those conducted in critical care patients can result in suboptimal echocardiograms. A suboptimal image is one in which two or more contiguous left ventricular segments in any of the three apical views cannot be visualized. The use of contrast in suboptimal echocardiograms may help with clinical evaluation of the patient.

For more information: www.lantheus.com

Related Content

CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
Arterys, Cardiac MRI, cardiac MRI advances

An example of the Arterys blood flow imaging assessment software that can help automate cardiac MRI. 

Feature | RSNA 2016 | January 30, 2017 | Dave Fornell
Each year imaging system manufacturers use the Radiological Society of North America (RSNA) meeting at the end of the
ultrasound systems market, $5 billion, 2023, GlobalData report
News | Ultrasound Imaging | January 25, 2017
The ultrasound systems space, which covers 39 major markets, is set to rise steadily from $4.2 billion in 2016 to $5...
Zika virus, imaging zika, radiology of Zika, medical imaging of zika

Prenatal MRI of a Zika fetus showing enlarged cerebral fluid space, dilation of the cerebral ventricles, thinning of brain tissue, poorly developed cerebellum and the absence of brain cortical gyri. (Image coutesy of RSNA)

Feature | Women's Health | January 23, 2017 | Dave Fornell
The rapid spread of Zika virus in the Western Hemisphere this past year has caused great alarm in the United States,
Konica Minolta, 7Dimaging, mskNAV Education Tool, musculoskeletal ultrasound, MSK, partnership
News | Ultrasound Imaging | January 20, 2017
Konica Minolta Healthcare Americas Inc. has partnered with 7Dimaging to strengthen its educational resources for...
GE Healthcare first, Vscan Extend, app-based ultrasound, dual-probe, RSNA 2017
Technology | Ultrasound Imaging | January 12, 2017
GE Healthcare unveiled its new generation of pocket-sized, dual-probe ultrasound, the Vscan Extend. From the hospital...
Sponsored Content | Videos | Ultrasound Imaging | January 10, 2017
Leveraging ZONARE’s revolutionary ZST and Mindray’s rich repertoire of workflow and user interface features, the Resona...
Hitachi, Vector Flow Mapping, TedMed 2016, Partho Sengupta, holographic evaluation of cardiac valves
News | Cardiovascular Ultrasound | January 04, 2017
January 4, 2017 — A new ground-breaking technology that allows evaluation of cardiac valves using holograms was demon
Toshiba Medical, Xario 200 Platinum Series ultrasound, RSNA 2016, SMI
Technology | Ultrasound Imaging | January 03, 2017
January 3, 2017 — Toshiba Medical introduced the Xario 200 Platinum Series...
MIM Software, BK Ultrasound, bkFusion, MRI Fusion Biopsy System, prostate cancer, RSNA 2016
Technology | Fusion Imaging Software | January 03, 2017
MIM Software Inc. announced in November the commercial introduction of its MRI (magnetic resonance imaging) Prostate...
Overlay Init